Forest plot for the significant MR association between four mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

Scatter plot for the significant Mendelian randomization (MR) association (P < 0.05) between mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

Presentation 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.pdf by Yi Li (1144)

“…</p>Conclusion<p>Prehospital TXA decreases early (24-h) mortality in trauma patients without a significant increase in the risk of VTE and other complications, and further studies are still needed to improve and optimize its management strategy.…”

Data Sheet 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.docx by Yi Li (1144)

“…</p>Conclusion<p>Prehospital TXA decreases early (24-h) mortality in trauma patients without a significant increase in the risk of VTE and other complications, and further studies are still needed to improve and optimize its management strategy.…”

Model-averaged coefficients, significance, and relative importance (RI) of the predictor variables for the GLMMs to evaluate effects on: (A) overall pollinator abundance; (B) fruit... by Carmelo Gómez-Martínez (9384385)

Three essential assumptions of the Mendelian randomization study. by Jing Wang (6206297)

Details of the GWAS data in this study. by Jing Wang (6206297)

“…</p><p>Results</p><p>This study shows that increases of anti-H. pylori IgG seropositivity was significantly associated with an increased risk of CHD (OR=1.003, 95% CI:1.0001.006, P = 0.048) and increases in peak insulin response (β = 0.214, 95% CI: 0.025–0.403, P = 0.026), decrease in total free cholesterol levels (β = ‒0.031, 95% CI: ‒0.061 to ‒0.000, P = 0.045), decreased waist circumference (β = ‒0.073, 95% CI: ‒0.138 to ‒0.008, P = 0.027) and waist-to-hip ratio (β = ‒0.069, 95% CI: ‒0.136 to ‒0.002, P = 0.044). …”

Mendelian randomization analysis of the effect of anti-H. pylori IgG seropositivity on coronary heart disease (CHD). by Jing Wang (6206297)

Publication bias of the risk of all groups. by Juan Gu (288925)

“…A period of 10–20 years since the last birth also showed a decreased risk (OR=0.867; 95% CI:0.747–1.007), whereas more than 20 years since the last birth was associated with an increased risk (OR = 1.304; 95% CI: 1.111–1.530).…”

Risk of bias. by Da Huang (1306407)

“…Furthermore, there was no significant difference in the change in resting heart rate (RHR) (MD = 2.04, 95% CI: −2.71–6.78; P = 0.40) between the physical activity group and the control group, but there was a significant difference in the change in maximum heart rate (HR-max) (MD = 6.27, 95% CI: 1.75–10.97, P = 0.007). …”

ROBINS-I assessments. by Martha R. Smith (20410184)

RoB 2 assessments. by Martha R. Smith (20410184)

S8 File - by Martha R. Smith (20410184)

“…However, significant gaps in the literature hinder the establishment of exercise as a targeted therapeutic strategy for pediatric metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD). …”

Study populations of included studies. by Martha R. Smith (20410184)

“…However, significant gaps in the literature hinder the establishment of exercise as a targeted therapeutic strategy for pediatric metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD). …”

Future research directions. by Martha R. Smith (20410184)

“…However, significant gaps in the literature hinder the establishment of exercise as a targeted therapeutic strategy for pediatric metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD). …”

PRISMA flow diagram. by Martha R. Smith (20410184)

“…However, significant gaps in the literature hinder the establishment of exercise as a targeted therapeutic strategy for pediatric metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD). …”

S9 File - by Martha R. Smith (20410184)

“…However, significant gaps in the literature hinder the establishment of exercise as a targeted therapeutic strategy for pediatric metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD). …”

S7 File - by Martha R. Smith (20410184)

“…However, significant gaps in the literature hinder the establishment of exercise as a targeted therapeutic strategy for pediatric metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD). …”

Participant characteristics of included studies. by Martha R. Smith (20410184)

“…However, significant gaps in the literature hinder the establishment of exercise as a targeted therapeutic strategy for pediatric metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD). …”

Risk of bias assessments for controlled trials. by Jesse Hill (19929059)